Cover Image
市場調查報告書

不孕症 (檢驗·治療)的全球市場的預測

GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

出版商 Inkwood Research 商品編碼 408538
出版日期 內容資訊 英文 135 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
不孕症 (檢驗·治療)的全球市場的預測 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026
出版日期: 2018年01月29日 內容資訊: 英文 135 Pages
簡介

本報告提供全球不孕症檢驗·治療的市場相關分析,提供您整體市場規模預測 (今後7年份) ,及男女·內容 (檢驗/治療)·地區別詳細趨勢,主要的推動及阻礙市場要素,市場競爭趨勢,主要企業簡介等相關調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 不孕症的原因和市場動態

  • 男性·女性不孕症
  • 推動市場要素與其影響度
  • 阻礙市場要素與其影響度
  • 市場機會
  • 市場課題

第5章 市場區隔

  • 男性不孕症
    • 男性不孕症檢驗的市場
    • 男性不孕症治療的市場
  • 女性不孕症
    • 女性不孕症檢驗的市場
      • 子宮輸卵管造影
      • 腹腔鏡檢驗
      • 經陰道超音波檢驗
      • 卵巢儲量檢驗
      • 荷爾蒙檢驗
      • 其他 (遺傳基因檢驗)
    • 女性不孕症治療的市場

第6章 主要分析指標

第7章 地區分析

  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國,法國,北歐各國,俄羅斯)
  • 亞洲 (中國,韓國,印度等)
  • 其他的國? (RoW)

第8章 競爭環境

  • ANDROLOGY SOLUTIONS
  • AUXILIUM SOLUTIONS
  • AUXOGYN
  • FERRING PHARMACEUTICALS
  • GENEA
  • HALOTECHDNA
  • IRVENE SCIENTIFIC
  • MERCK SERONO
  • ORIGIO
  • OVASCIENCE

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1961

KEY FINDINGS:

A global rise in infertility and increasing awareness about its effective treatments, combined with the emergence of medical tourism in fertility treatments are propelling the global infertility testing and treatment market. By the end of the forecast period of 2018 - 2026, the market is predicted to evolve at 6.39% CAGR.

MARKET INSIGHTS:

The global infertility testing and treatment market is segmented on the basis of male infertility, female infertility and end-users. Both the male and female infertility markets are further sub-segmented into testing and treatment. Increasing number of couples are opting for IVF techniques, and as a result, the female infertility treatment segment is dominating the market. The end-users for this market are sub-segmented into hospitals and research laboratories, fertility and surgical centers, and cryobanks.

REGIONAL INSIGHTS:

Asia-Pacific, Europe, North America and rest of the world are the markets focused for the global infertility testing and treatment market. The European market is expected to capture the highest market share by the end of the estimated period. The region has a presence of a number of IVF clinics that provide treatments at reasonable costs. The APAC market is also forecasted to exhibit a significant growth over the forecast period, driven by a low birth rate and favourable government initiatives in countries like Taiwan, South Korea, Singapore and Japan.

COMPETITIVE INSIGHTS:

Major companies dealing in the infertility testing and treatment market include Endo Pharmaceuticals, Andrology Solutions, Progyny, Genea, Ferring Pharmaceuticals, Halotech DNA, Merck, Irvine Scientific, Origio, Vitrolife Ab, Ovascience, Thermo Fisher Scientific Inc, Quest Diagnostic, The Cooper Companies, Inc, Esco Micro Pte. Ltd, Alere, Elucigene, Celmatrix, Claritas Genomics, Veritas Genetics, Roche, Agilent, LabCorp, Integrated Genetics, Centogene, Phosphorus Diagnostics, Natera Inc, and Illumina Inc.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. EUROPE IS THE LARGEST MARKET
    • 3.2.2. ASIA PACIFIC IS THE FASTEST GROWING REGION IN THE INFERTILITY MARKET
    • 3.2.3. IVF DOMINATES THE FEMALE TREATMENT MARKET
    • 3.2.4. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

4. MARKET OVERVIEW

  • 4.1. MARKET DEFINITION
  • 4.2. MARKET DRIVERS AND IMPACT
    • 4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
    • 4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
    • 4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
    • 4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED THE FERTILITY TREATMENT
    • 4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
    • 4.2.6. HEALTHIER DONOR EGGS
    • 4.2.7. INTRODUCTION OF NEW TESTING DEVICES
  • 4.3. RESTRAINTS AND IMPACT
    • 4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
    • 4.3.2. COUNTRY-WISE REGULATORY ISSUES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
    • 4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
    • 4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
  • 4.5. MARKET CHALLENGES
    • 4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
    • 4.5.2. PERILS OF MULTIPLE PREGNANCIES
    • 4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO INFERTILITY TREATMENTS
      • 4.5.3.1. DIET AND SUPPLEMENTS
      • 4.5.3.2. ACUPUNCTURE
      • 4.5.3.3. THERAPY
      • 4.5.3.4. QIGONG

5. INFERTILITY CAUSES

  • 5.1. CAUSES OF MALE INFERTILITY
    • 5.1.1. ABNORMALITY IN THE SPERM
    • 5.1.2. ENVIRONMENTAL FACTORS
    • 5.1.3. POOR HEALTH AND LIFESTYLE
  • 5.2. CAUSES OF FEMALE INFERTILITY
    • 5.2.1. OVULATION DISORDERS
    • 5.2.2. DAMAGE TO FALLOPIAN TUBES
  • 5.3. MORAL QUESTIONS

6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)

  • 6.1. MARKET BY MALE INFERTILITY TESTING
    • 6.1.1. DNA FRAGMENTATION
    • 6.1.2. OXIDATIVE STRESS ANALYSIS
    • 6.1.3. SPERM PENETRATION ASSAY
    • 6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
    • 6.1.5. SPERM AGGLUTINATION
    • 6.1.6. MICROSCOPIC EXAMINATION
    • 6.1.7. OTHERS
  • 6.2. MARKET BY MALE INFERTILITY TREATMENT
    • 6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
    • 6.2.2. SPERM RETRIEVAL TREATMENT
    • 6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
    • 6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
    • 6.2.5. VARICOCELE REPAIRS
    • 6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
    • 6.2.7. INTRAUTERINE INSEMINATION (IUI)
    • 6.2.8. IN VITRO FERTILIZATION (IVF)
    • 6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)

7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)

  • 7.1. MARKET BY FEMALE INFERTILITY TESTING
    • 7.1.1. OVULATION TESTING
    • 7.1.2. HYSTEROSALPINGOGRAPHY
    • 7.1.3. LAPAROSCOPY
    • 7.1.4. TRANSVAGINAL ULTRASOUND
    • 7.1.5. OVARIAN RESERVE TESTING
    • 7.1.6. HORMONAL LEVEL TESTING
    • 7.1.7. OTHERS (GENETIC TESTING)
  • 7.2. MARKET BY FEMALE INFERTILITY TREATMENT
    • 7.2.1. IN VITRO FERTILIZATION
    • 7.2.2. INTRAUTERINE INSEMINATION (IUI)
    • 7.2.3. DRUG AND HORMONE THERAPIES

8. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)

  • 8.1. FERTILITY AND SURGICAL CENTERS
  • 8.2. HOSPITALS AND RESEARCH LABORATORIES
  • 8.3. CRYOBANKS

9. KEY ANALYTICS

  • 9.1. PORTER'S 5 FORCE MODEL
    • 9.1.1. THREAT OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
    • 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 9.2. VALUE CHAIN ANALYSIS
    • 9.2.1. RAW MATERIAL PROCUREMENT
    • 9.2.2. MANUFACTURING
    • 9.2.3. SUPPLY LOGISTICS
    • 9.2.4. DISTRIBUTION CHANNELS
    • 9.2.5. END USERS
  • 9.3. KEY BUYING CRITERIA
    • 9.3.1. TREATMENT OPTIONS
    • 9.3.2. QUALITY OF MEDICAL PROCEDURES
    • 9.3.3. PRICE OF TREATMENTS
    • 9.3.4. SHIFT TOWARDS MEDICAL TOURISM
    • 9.3.5. REIMBURSEMENT
  • 9.4. REGULATORY FRAMEWORK
  • 9.5. KEY TRENDS
    • 9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
    • 9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
    • 9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
    • 9.5.4. REGULATORY ENVIRONMENT- KEY MARKET ENABLER
    • 9.5.5. MORE COUPLES OPTING FOR SURROGACY
    • 9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
  • 9.6. VENDOR LANDSCAPE
  • 9.7. OPPORTUNITY MATRIX

10. KEY ANALYTICS - TESTING MARKET

  • 10.1. PORTER'S 5 FORCE ANALYSIS
    • 10.1.1. THREAT OF NEW ENTRANTS
    • 10.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 10.1.3. BARGAINING POWER OF BUYERS
    • 10.1.4. BARGAINING POWER OF SUPPLIERS
    • 10.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 10.2. KEY BUYING CRITERIA
  • 10.3. VENDOR LANDSCAPE
  • 10.4. OPPORTUNITY MATRIX

11. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET REGIONAL ANALYSIS 2018-2026 ($ MILLION)

  • 11.1. NORTH AMERICA
    • 11.1.1. US
    • 11.1.2. CANADA
  • 11.2. ASIA PACIFIC
    • 11.2.1. CHINA
    • 11.2.2. INDIA
    • 11.2.3. JAPAN
    • 11.2.4. SOUTH KOREA
    • 11.2.5. REST OF ASIA-PACIFIC
  • 11.3. EUROPE
    • 11.3.1. UK
    • 11.3.2. GERMANY
    • 11.3.3. FRANCE
    • 11.3.4. NORDICS
    • 11.3.5. RUSSIA
  • 11.4. REST OF THE WORLD

12. COMPETITIVE ANALYSIS

  • 12.1. ANDROLOGY SOLUTIONS
    • 12.1.1. OVERVIEW
    • 12.1.2. PRODUCT PORTFOLIO
    • 12.1.3. SCOT ANALYSIS
  • 12.2. ENDO PHARMACEUTICALS
    • 12.2.1. OVERVIEW
    • 12.2.2. PRODUCT PORTFOLIO
    • 12.2.3. STRATEGIC MOVES
    • 12.2.4. SCOT ANALYSIS
  • 12.3. PROGYNY
    • 12.3.1. OVERVIEW
    • 12.3.2. PRODUCT PORTFOLIO
    • 12.3.3. STRATEGIC MOVES
    • 12.3.4. SCOT ANALYSIS
  • 12.4. FERRING PHARMACEUTICALS
    • 12.4.1. OVERVIEW
    • 12.4.2. PRODUCT PORTFOLIO
    • 12.4.3. STRATEGIC MOVES
    • 12.4.4. SCOT ANALYSIS
  • 12.5. GENEA
    • 12.5.1. OVERVIEW
    • 12.5.2. PRODUCT PORTFOLIO
    • 12.5.3. STRATEGIC MOVES
    • 12.5.4. SCOT ANALYSIS
  • 12.6. HALOTECH DNA
    • 12.6.1. OVERVIEW
    • 12.6.2. PRODUCT PORTFOLIO
    • 12.6.3. STRATEGIC MOVES
    • 12.6.4. SCOT ANALYSIS
  • 12.7. IRVINE SCIENTIFIC
    • 12.7.1. OVERVIEW
    • 12.7.2. PRODUCT PORTFOLIO
    • 12.7.3. STRATEGIC MOVES
    • 12.7.4. SCOT ANALYSIS
  • 12.8. MERCK
    • 12.8.1. OVERVIEW
    • 12.8.2. PRODUCT PORTFOLIO
    • 12.8.3. STRATEGIC MOVES
    • 12.8.4. SCOT ANALYSIS
  • 12.9. ORIGIO
    • 12.9.1. OVERVIEW
    • 12.9.2. PRODUCT PORTFOLIO
    • 12.9.3. STRATEGIC MOVES
    • 12.9.4. SCOT ANALYSIS
  • 12.10. OVASCIENCE
    • 12.10.1. OVERVIEW
    • 12.10.2. PRODUCT PORTFOLIO
    • 12.10.3. STRATEGIC MOVES
    • 12.10.4. SCOT ANALYSIS
  • 12.11. VITROLIFE AB
    • 12.11.1. OVERVIEW
    • 12.11.2. PRODUCT PORTFOLIO
    • 12.11.3. STRATEGIC MOVES
    • 12.11.4. SCOT ANALYSIS
  • 12.12. THERMO FISHER SCIENTIFIC INC
    • 12.12.1. OVERVIEW
    • 12.12.2. PRODUCT PORTFOLIO
    • 12.12.3. STRATEGIC MOVES
    • 12.12.4. SCOT ANALYSIS
  • 12.13. THE COOPER COMPANIES, INC
    • 12.13.1. OVERVIEW
    • 12.13.2. PRODUCT PORTFOLIO
    • 12.13.3. STRATEGIC MOVES
    • 12.13.4. SCOT ANALYSIS
  • 12.14. QUEST DIAGNOSTIC
    • 12.14.1. OVERVIEW
    • 12.14.2. PRODUCT PORTFOLIO
    • 12.14.3. SCOT ANALYSIS
    • 12.14.4. STRATEGIC MOVES
  • 12.15. ESCO MICRO PTE. LTD.
    • 12.15.1. OVERVIEW
    • 12.15.2. PRODUCT PORTFOLIO
    • 12.15.3. STRATEGIC MOVES
    • 12.15.4. SCOT ANALYSIS
  • 12.16. ELUCIGENE
    • 12.16.1. OVERVIEW
    • 12.16.2. PRODUCT PORTFOLIO
    • 12.16.3. SCOT ANALYSIS
    • 12.16.4. STRATEGIC INITIATIVE
  • 12.17. ALERE
    • 12.17.1. OVERVIEW
    • 12.17.2. PRODUCT PORTFOLIO
    • 12.17.3. SCOT ANALYSIS
    • 12.17.4. STRATEGIC INITIATIVE
  • 12.18. CELMATRIX
    • 12.18.1. OVERVIEW
    • 12.18.2. PRODUCT PORTFOLIO
    • 12.18.3. SCOT ANALYSIS
    • 12.18.4. STRATEGIC INITIATIVE
  • 12.19. VERITAS GENETICS
    • 12.19.1. OVERVIEW
    • 12.19.2. PRODUCT PORTFOLIO
    • 12.19.3. SCOT ANALYSIS
    • 12.19.4. STRATEGIC INITIATIVE
  • 12.20. CLARITAS GENOMICS
    • 12.20.1. OVERVIEW
    • 12.20.2. PRODUCT PORTFOLIO
    • 12.20.3. SCOT ANALYSIS
    • 12.20.4. STRATEGIC INITIATIVE
  • 12.21. ROCHE
    • 12.21.1. OVERVIEW
    • 12.21.2. PRODUCT PORTFOLIO
    • 12.21.3. SCOT ANALYSIS
    • 12.21.4. STRATEGIC INITIATIVE
  • 12.22. LABCORP
    • 12.22.1. OVERVIEW
    • 12.22.2. PRODUCT PORTFOLIO
    • 12.22.3. SCOT ANALYSIS
    • 12.22.4. STRATEGIC INITIATIVE
  • 12.23. AGILENT
    • 12.23.1. OVERVIEW
    • 12.23.2. PRODUCT PORTFOLIO
    • 12.23.3. SCOT ANALYSIS
    • 12.23.4. STRATEGIC INITIATIVE
  • 12.24. INTEGRATED GENETICS
    • 12.24.1. OVERVIEW
    • 12.24.2. PRODUCT PORTFOLIO
    • 12.24.3. SCOT ANALYSIS
  • 12.25. PHOSPHORUS DIAGNOSTICS
    • 12.25.1. OVERVIEW
    • 12.25.2. PRODUCT PORTFOLIO
    • 12.25.3. SCOT ANALYSIS
    • 12.25.4. STRATEGIC INITIATIVE
  • 12.26. CENTOGENE
    • 12.26.1. OVERVIEW
    • 12.26.2. PRODUCT PORTFOLIO
    • 12.26.3. SCOT ANALYSIS
    • 12.26.4. STRATEGIC INITIATIVE
  • 12.27. NATERA INC
    • 12.27.1. OVERVIEW
    • 12.27.2. PRODUCT PORTFOLIO
    • 12.27.3. SCOT ANALYSIS
    • 12.27.4. STRATEGIC INITIATIVE
  • 12.28. ILLUMINA INC
    • 12.28.1. OVERVIEW
    • 12.28.2. PRODUCT PORTFOLIO
    • 12.28.3. SCOT ANALYSIS
    • 12.28.4. STRATEGIC INITIATIVE

LIST OF TABLES

  • TABLE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 ($ MILLION)
  • TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
  • TABLE 3 GLOBAL MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
  • TABLE 4 GLOBAL MALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
  • TABLE 5 PROS AND CONS OF DNA SHARING METHODS
  • TABLE 6 GLOBAL DNA FRAGMENTATION MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 7 GLOBAL OXIDATIVE STRESS ANALYSIS MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 8 GLOBAL SPERM PENETRATION ASSAY MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 9 GLOBAL CASA MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 10 GLOBAL SPERM AGGLUTINATION MARKET BY REGION2018-2026 ($MILLION)
  • TABLE 11 GLOBAL MICROSCOPIC EXAMINATION MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 12 GLOBAL FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
  • TABLE 13 GLOBAL FEMALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
  • TABLE 14 COST OF OVULATION TESTING KITS IN THE US
  • TABLE 15 GLOBAL OVULATION TESTING MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 16 GLOBAL HYSTEROSALPINGOGRAPHY MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 17 GLOBAL LAPAROSCOPY MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 18 GLOBAL TRANSVAGINAL ULTRASOUND MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 19 GLOBAL OVARIAN RESERVE TESTING MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 20 GLOBAL HORMONAL LEVEL TESTING MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 21 COST OF HORMONAL TEST IN THE US
  • TABLE 22 GLOBAL FEMALE INFERTILITY TREATMENT MARKET 2018-2026 ($ MILLION)
  • TABLE 23 AVERAGE COST OF SOME INFERTILITY TREATMENTS
  • TABLE 24 GLOBAL IVF TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 25 GLOBAL IUI TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 26 GLOBAL DRUG AND HORMONE THERAPIES MARKET BY REGION 2018-2026 ($MILLION)
  • TABLE 27 SOME COMMON DRUG THERAPIES
  • TABLE 28 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
  • TABLE 29 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 30 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 31 GLOBAL CRYOBANKS MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 32 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 33 NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($ MILLION)
  • TABLE 34 SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) USING DONOR EGGS IN THE U.S. IN 2013
  • TABLE 35 COSTS FOR INFERTILITY TREATMENTS IN THE U.S. 2015
  • TABLE 36 COST OF IVF & ICSI TREATMENT, CANADA 2014
  • TABLE 37 ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
  • TABLE 38 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
  • TABLE 39 COST OF IVF IN RUSSIA

LIST OF FIGURES

  • FIGURE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
  • FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
  • FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
  • FIGURE 4 RATE OF MULTIPLE DELIVERIES
  • FIGURE 5 CAUSES OF INFERTILITY
  • FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
  • FIGURE 7CAUSES OF SPERM DNA FRAGMENTATION
  • FIGURE 8 WORLDWIDE FALLING FERTILITY RATE (TOTAL BIRTHS PER WOMAN)
  • FIGURE 9 NUMBER OF IVF CYCLES PERFORMED IN THE US
  • FIGURE 10 US INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 11 CANADA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 12 GROWTH IN IVF CLINICS IN ASIA
  • FIGURE 13 CHINA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
  • FIGURE 14 INDIA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
  • FIGURE 15 JAPAN INFERTILITY TESTING AND TREATMENT MARKET2018-2026(MILLION)
  • FIGURE 16 SOUTH KOREA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (MILLION)
  • FIGURE 17 MEDICAL TOURISM IN SOUTH KOREA ($ MILLION)
  • FIGURE 18 REST OF ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
  • FIGURE 19 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 20 FERTILITY TREATMENT IN 2014
  • FIGURE 21 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 22 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 23 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 24 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
  • FIGURE 25 REST OF THE WORLD INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
Back to Top